Development

GVV858 Phase 1 Trial: Targeting CCNE1-Amplified Advanced Solid Tumors in Breast and Prostate Cancer

Edited by Robert McTiernan··1 min read

Novel Cancer Therapy GVV858 Enters First-in-Human Trial Targeting Advanced Solid Tumors

A first-in-human clinical trial for GVV858, a novel investigational drug targeting advanced solid tumors, has begun recruiting patients with hormone receptor-positive, HER2-negative breast cancer and metastatic castration-resistant prostate cancer. The phase 1 trial (NCT07288359) will evaluate the safety, tolerability, and preliminary efficacy of the molecule across multiple cancer types with CCNE1 amplification.

The trial will employ a standard dose-escalation design, with an anticipated enrollment of approximately 120 participants across sites in the United States and Singapore. Investigators will assess dose-limiting toxicities, maximum tolerated dose, and preliminary anti-tumor activity, with primary endpoints focused on safety and pharmacokinetic characteristics of GVV858.

Research context

The trial emerges in a rapidly evolving landscape of targeted therapies for CCNE1-amplified cancers. Current treatment approaches for hormone receptor-positive breast cancer and metastatic prostate cancer remain limited, with significant unmet medical needs persisting for patients who have progressed through standard therapies.

The AllSci BriefSystematic R&D and deal news. Daily.

Recent developments in the field include emerging CDK2 and WEE1 inhibitors from companies like Incyclix Bio, Novartis, and NiKang Therapeutics. These molecules target similar molecular pathways, with several phase 1/2 trials currently investigating novel approaches to interrupting cell cycle progression in cancer cells.

The CCNE1 inhibitor landscape remains nascent, with no phase 3 trials yet reported. Most current research focuses on phase 1/2 investigations targeting breast, ovarian, and other solid tumors with specific molecular alterations. The GVV858 trial represents another important step in understanding potential therapeutic interventions for these challenging cancer types.

While the specific originating institution for GVV858 remains unclear from available data, the trial's multicenter design suggests a collaborative approach to evaluating this novel therapeutic candidate.

Spot something wrong? Report an issue with this article